Company Announcements

Fractyl Health Gains FDA Nod to Investigate Revita Device

Fractyl Health, Inc. (GUTS) just unveiled an update.

Fractyl Health, Inc. has announced a significant milestone with the FDA granting it Investigational Device Exemption to explore the effectiveness of its Revita device in sustaining weight loss after patients stop using GLP-1 receptor agonist drugs. This development, along with other recent updates, has been incorporated into a new corporate presentation, accessible on the company’s investor relations website. This move marks a promising step forward for the company in the weight management medical device market.

Learn more about GUTS stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskFractyl Health Reports Q3 2024 Financial Performance
TipRanks Auto-Generated NewsdeskFractyl Health Unveils Promising Gene Therapy Data
TheFlyFractyl Health presented new analysis of Revita studies at ObesityWeek 2024
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App